Franklin Greif, Ziv Ben‐Ari, Rasim Taya, Orit Pappo, Efrat Kurtzwald, Yelena Cheporko, Amiram Ravid, Edith Hochhauser – 8 February 2010 – The only currently offered curative option for many patients with primary or secondary liver tumors is the resection of hepatic tumors. The aim of this study was to evaluate the role of recombinant human erythropoietin (rhEPO) in liver protection and regeneration after subtotal hepatectomy in rats. Rats undergoing 70% hepatectomy received an intraperitoneal injection of saline (control) or rhEPO (4 U/g) 30 minutes prior to resection.

Fabio Piscaglia, Alice Gianstefani, Matteo Ravaioli, Rita Golfieri, Alberta Cappelli, Emanuela Giampalma, Elisabetta Sagrini, Grazia Imbriaco, Antonio Daniele Pinna, Luigi Bolondi – 8 February 2010 – Malignant portal vein thrombosis is a contraindication for liver transplantation. Patients with cirrhosis and early hepatocellular carcinoma (HCC) may have either malignant or benign (fibrin clot) portal vein thrombosis.

Zeeshan Butt,, Daniela Ladner, Neehar Parikh – 8 February 2010

Manuel Romero‐Gómez, Moisés Diago, Raúl J. Andrade – 28 January 2010

Alberto Quaglia, Ahlam Mustafa, Ragai R. Mitry, Bernard Portmann – 28 January 2010

Kenji Nakayama, Mamoru Tamura – 28 January 2010

Chia‐Chi Wang, Jia‐Horng Kao – 28 January 2010

Rebecca G. Wells – 27 January 2010

Chung‐Shun Wong, Wei‐Chen Lee, Chang‐Chyi Jenq, Ya‐Chung Tian, Ming‐Yang Chang, Chan‐Yu Lin, Ji‐Tseng Fang, Chih‐Wei Yang, Ming‐Hung Tsai, Hsin‐Chin Shih, Yung‐Chang Chen – 26 January 2010 – Liver transplantation can prolong survival and improve the quality of life of patients with end‐stage liver disease. This study retrospectively reviewed the medical records of 149 patients who had received liver transplants in a tertiary care university hospital from January 2000 to December 2007. Demographic, clinical, and laboratory variables were recorded.

Geoffrey W. McCaughan, Nicholas A. Shackel, Simone I. Strasser, Pamela Dilworth, Patrick Tang – 26 January 2010 – Although 1‐year survival rates following liver transplantation over the last 20 years may have improved, there is doubt about improvement in long‐term survival. We examined survival with and without initial 12‐month mortality in adult liver transplant recipients over a 20‐year period. Patient and allograft survival for 3 different time periods was compared: 1986‐1994 (group 1, n = 547), 1995‐2000 (group 2, n = 735), and 2000‐2005 (group 3, n = 749).